Abstract
p21WAF1/CIP1 protein is a cyclin-dependent kinase inhibitor, able to prevent the CDK2/cyclin E induced retinoblastoma protein (pRB) phosphorylation, thus inhibiting cell cycle progression at G1 phase. p21WAF1/CIP1 protein levels were examined in a series of 102 ovarian tissue samples including normal ovary, primary ovarian tumors, omental metastasis, recurrent disease and residual tumor after chemotherapy exposure, by Western blot analysis. The association of p21WAF1/CIP1 status with clinicopathological parameters and clinical outcome was also investigated. p21WAF1/CIP1 protein was detectable in 76 out of 102 (74%) ovarian tissue samples. We observed a significant trend of p21 levels to gradually increase from normal ovarian tissues (median 0 a.u.) through primary ovarian cancers (median 0.19 a.u.), omental metastases (median 0.33 a.u.) and recurrence of disease (median 0.44 a.u.) (p=0.015). In the group of stage III-IV ovarian cancer patients, p21-positive cases showed a more favourable prognosis with respect to p21-negative cases: the 3-year time to progression (TTP) rate was 58% for p21-positive compared with 33% of p21-negative cases (p=0.036). In conclusion, p21WAF1/CIP1 expression levels seem to be correlated with tumor status at the time of diagnosis and can predict TTP in a selected group of patients.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Carcinoma, Endometrioid / drug therapy
-
Carcinoma, Endometrioid / genetics
-
Carcinoma, Endometrioid / metabolism
-
Carcinoma, Endometrioid / pathology
-
Carcinoma, Endometrioid / secondary
-
Carcinoma, Endometrioid / surgery
-
Cell Cycle
-
Cisplatin / administration & dosage
-
Cyclin-Dependent Kinase Inhibitor p21
-
Cyclins / biosynthesis*
-
Cyclins / genetics
-
Cystadenocarcinoma, Mucinous / drug therapy
-
Cystadenocarcinoma, Mucinous / genetics
-
Cystadenocarcinoma, Mucinous / metabolism
-
Cystadenocarcinoma, Mucinous / pathology
-
Cystadenocarcinoma, Mucinous / secondary
-
Cystadenocarcinoma, Mucinous / surgery
-
Cystadenocarcinoma, Serous / drug therapy
-
Cystadenocarcinoma, Serous / genetics
-
Cystadenocarcinoma, Serous / metabolism*
-
Cystadenocarcinoma, Serous / pathology
-
Cystadenocarcinoma, Serous / secondary
-
Cystadenocarcinoma, Serous / surgery
-
Disease Progression
-
Female
-
Gene Expression Regulation, Neoplastic*
-
Genes, p53
-
Humans
-
Life Tables
-
Middle Aged
-
Neoplasm Proteins / biosynthesis*
-
Neoplasm Proteins / genetics
-
Neoplasm Recurrence, Local
-
Neoplasm Staging
-
Neoplasm, Residual
-
Omentum
-
Ovarian Neoplasms / drug therapy
-
Ovarian Neoplasms / genetics
-
Ovarian Neoplasms / metabolism*
-
Ovarian Neoplasms / pathology
-
Ovarian Neoplasms / surgery
-
Ovary / metabolism
-
Peritoneal Neoplasms / metabolism
-
Peritoneal Neoplasms / secondary
-
Survival Analysis
-
Treatment Outcome
Substances
-
CDKN1A protein, human
-
Cyclin-Dependent Kinase Inhibitor p21
-
Cyclins
-
Neoplasm Proteins
-
Cisplatin